Home › Funds › Defilade Capital Management, L.P. › MREO
Defilade Capital Management, L.P. position in MREO
MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS · Health Care
Defilade Capital Management, L.P. reported holding 7,558,756 shares of MREO (MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS) in its Q2 2026 13F filing — a position valued at US$2.4M, representing 0.32% of its reported portfolio and ranking #39 among its reported holdings. Defilade Capital Management, L.P. has disclosed MREO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Defilade Capital Management, L.P.'s MREO position evolved
Defilade Capital Management, L.P. first disclosed a stake in MREO in Q1 2026 at 7,558,756 shares (US$2.5M). Across 2 filings, Defilade Capital Management, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 7,558,756 shares valued at US$2.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 7.56M | $2.49M | New |
| Q2 2026 | 7.56M | $2.40M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MREO and 13F data
MREO (MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS) is a Health Care company. 4 other funds we track also report a position in MREO — the largest reported positions include Newtyn Management, LLC (US$953K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MREO
- Newtyn Management, LLC 3.00M sh · $953.10K · Q2 2026
More on Defilade Capital Management, L.P.
FAQ
How long has Defilade Capital Management, L.P. held MREO?
Defilade Capital Management, L.P. has disclosed MREO holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Defilade Capital Management, L.P.'s current position in MREO?
As of Q2 2026, Defilade Capital Management, L.P. holds 7.56M shares of MREO (MEREO BIOPHARMA GROUP FUNSPONSORED ADR 1 ADR REPS 5 ORD SHS), valued at $2.40M, representing 0.32% of its reported portfolio and ranking #39.
Has Defilade Capital Management, L.P. been buying or selling MREO?
In the latest 13F filing (Q2 2026), Defilade Capital Management, L.P. held unchanged its position in MREO.
Which other funds hold MREO?
Other major institutional holders of MREO include Newtyn Management, LLC, among 4 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.